Disc Medicine, Inc. announced the appointment of Jean Franchi as the company?s Chief Financial Officer. Ms. Franchi will be responsible for finance, investor relations, and other functions and will lead the company?s capital formation and financial strategy. She succeeds Joanne Bryce, who will transition to a consulting role with the company.

Ms. Franchi is an experienced CFO with over 30 years of finance leadership expertise at both public and private biotechnology companies of varying sizes across all stages of development. Most recently, she was the Chief Financial Officer of Replimune where she helped raise over $750 million across multiple financings and non-dilutive debt, supporting significant expansion while providing optionality in future capital formation for Replimune?s portfolio. Prior to Replimune, Ms. Franchi served as Chief Financial Officer for Merrimack Pharmaceuticals, Dimension Therapeutics, which was acquired by Ultragenyx, and Good Start Genetics.

Ms. Franchi spent 16 years at Genzyme advancing within the organization during its most rapid phase of growth. Ms. Franchi spent eight years at Genzyme as the Senior Vice President of Finance for all nine business units and then Senior Vice President of Corporate Finance working alongside the Chief Financial Officer and playing an important role in the approximately $20.1 billion sale to Sanofi. Ms. Franchi holds a Bachelor's degree in Business Administration from Hofstra University.